Spyre Therapeutics, Inc.
SYRE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $5,800 | $909 | $973 | $1,095 |
| - Cash | $65 | $82 | $48 | $89 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $5,735 | $827 | $924 | $1,005 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$45 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$11 | -$52 | -$54 | -$61 |
| % Margin | – | – | – | – |
| Net Income | -$11 | -$37 | -$45 | -$56 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.15 | -0.6 | -0.13 | -0.15 |
| % Growth | 75% | -361.5% | 13.3% | – |
| Operating Cash Flow | -$37 | -$47 | -$41 | -$37 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$37 | -$47 | -$41 | -$37 |